Moderna (MRNA) Stock Climbs On Positive COVID-19 Vaccine Data

Moderna MRNA Stock News

Moderna Inc (NASDAQ: MRNA) is making a run for the top in the market this morning, trading on gains of more than 30%, and for good reason. Early this morning, the company issued a press release, announcing positive data from its COVID-19 vaccine candidate. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

MRNA Stock Flies On Positive COVID-19 Vaccine Results

In  the press release, Moderna provided positive interim data from mRNA-1273. mRNA-1273 is the company’s vaccine against the novel coronavirus, the virus causing the COVID-19 pandemic.

The data came from a Phase 1 study led by the National Institute of Allergy and Infectious Disease (NIAID).

In the release, MRNA said that immunogenicity data are curently available for two dose levels after two doses and one dose level after a single dose administration. Importantly, dose-dependent increases in immunogenicity were seen across all three dose levels.

The company also said that all participants ages 18 to 55 across all three dose levels seroconverted by day 15 after a single dose. The company also said that two weeks after the second dose, levels of binding antibodies were at the levels seen in convalescent sera in the smallest dose cohort.

Importantly, at the middle dose cohort, levels of binding antibodies significantly exceeded the levels seen in convalescent sera. However, MRNA said that the results from remaining participants are not yet available.

Modernal also said that the first two dose cohorts showed that the vaccine elicited neutralizing antibodies in all eight participants. These neutralizing antibody levels at day 43 were above levels generally seen in convalescent sera.

Along with efficacy data, MRNA said that the vaccine is proving to be safe and well tolerated. There was only one incidence of a grade 3 adverse event. This event was redness around the injection site. However, all adverse events in the trial have been self-resolving and no serious adverse events have been seen.

In a statement, Tal Zaks, M.D., Ph.D., CMO at MRNA, had the following to offer:

These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg. When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.

This Is Huge News

There’s no doubt that there are plenty of competitors racing to develop the first novel coronavirus vaccine. However, based on today’s news, there’s no doubt that MRNA is well ahead of the competition here.

Not only does the company have a vaccine candidate in human clinical trials, those trials seem to be going well. Should the data continue to be so positive, the company could become the first to bring a COVID-19 vaccine to market.

Of course, the demand for such a vaccine is incredibly high around the globe. So, should the company develop the first effective option, revenue will likely see a substantial increase. All in all, MARK stock is one that should be on your watchlist.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.